Changes in Hong Kong stocks | China Biopharmaceutical (01177) opened more than 6% after the performance, and reached a new high of 19.44 billion yuan in the first half of the year and continued to win endorsements from the world's top pharmaceutical companies

The Zhitong Finance App learned that China Biopharmaceuticals (01177) opened more than 6% higher after the results. As of press release, it had risen 6.05% to HK$5.08, with a turnover of HK$15.734,500.

According to the news, on August 19, China Biopharmaceuticals officially announced its 2026 interim results. The data showed a rare high growth trend. Not only did revenue reach a record high of 19.44 billion yuan, up 10.6% year on year, but the adjusted net profit from the core business also achieved a steady increase of 3.34 billion yuan, with a year-on-year growth rate of 92.3%. In the first half of 2026, with the approval of innovative products such as lovacitinib, peleganam, and naltimidine, as well as the further expansion of indications for core products such as anlotinib, coumosilil, and zoneitinib, the company's innovative business is entering a period of centralized cashing.

It is worth mentioning that in the first half of the year, Zhongsheng continued to win endorsements from the world's top pharmaceutical companies through innovation at the source. Up to now, the Group has completed 4 major external licenses, with a total transaction scale of over 7 billion US dollars, and a total down payment of more than 1 billion US dollars. This means that Zhongsheng's R&D strength and production quality control have been fully certified by the world's top MNC, and BD is moving towards “normalized export.” At the same time, under the two major strategic banners of AI and internationalization, the thickness of the pipeline in the four core treatment fields of oncology, liver disease/cardiovascular metabolism, breathing/self-immunity, and surgery/analgesia is being transformed into intensive commercialization results.